Chronic lower back pain (CLBP) is a major economic burden on individuals, healthcare system and society as a whole. Spinal fusion surgery is recommended in patients with persistent pain. Most lumbar spinal fusion surgery involves the use of bone autograft from patient's iliac crest, which implies increased co-morbidity. InductOs® is indicated for single-level (L4 - S1) anterior lumbar spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease (DDD). OBJECTIVE: To evaluate the potential economic benefits of InductOs® compared to autograft, in spinal fusions in patients with DDD in Spain. METHODS: An analytic decision tree model was developed in order to simulate the clinical pathways of a cohort of 1000 simulated patients with DDD. The analysis was performed from the perspective Spanish National Health System (payer), with a time horizon of 2 years. Clinical and economical data were retrieved from published studies and official tariffs, validated by a clinician trained in the management of these patients in the Spanish setting. RESULTS: In Spain, the use of InductOs® leads to a reduction in operation times and length of stay resulting in savings of €930 per patient, to a reduction of revisional spinal procedures resulting in further savings of €428 per patient, and to a faster return to work by an average of 54 days, resulting in additional savings of €2304 per patient from sickness-leave payments avoided. These savings offset the upfront cost of InductOs® of 2799 resulting in net cost savings of €863 per case treated, as compared to standard care. CONCLUSION: Adding InductOs® to the standard care in CLBP is a cost saving strategy in the Spanish setting.